Luxsky Lighting Co.,Limited

Tel:0086-755-82590839
Contact US
Address: C&H Building, Wanda Industrial Park, Shiyan Town, Bao'an district, Shenzhen City, China
TEL: +86-755-82590839
+86-755-33654459
FAX : +86-755-33654451
Home > Exhibition > Content
Major breakthrough: LED lamp can be used for diabetes diagnosis and treatment!
- Jul 15, 2017 -


LED industry's rapid development, not only used in our daily lighting life, but also with its innovative application in various fields, such as the diagnosis of disease!

The world famous academic journal Science Translational Medicine (translational –) website, recently published the East China Normal University researcher Yehai team's latest research results. This study has been implemented for the first time through the intelligent mobile phone remote control treatment of diabetes, is expected for the future clinical integration, accurate treatment of diabetes to provide new ideas and strategies.

Left: Research correspondent Yehai researcher; Right: The first author of this study Shao Jiawei

In recent years, with the continuous innovation of mobile communication technology, the rapid development of smart phones, also become an indispensable part of action medical treatment, has been used in blood sugar monitoring. However, at present, only the diagnosis and detection of diabetic patients, can not achieve treatment. As a result, the team of Yehai researchers at the ECNU Institute of Life Sciences has cleverly combined synthetic biology with electronic engineering to develop a new intelligent diagnosis and treatment system that integrates diabetes diagnostics and therapy.

A new intelligent diagnosis and treatment system integrated with diabetes mellitus

The system has two main features: first, the researchers can control the gene expression by ecnu-telemed app over remote red brightness in the mobile phone. Second, the blood sugar signal of diabetic white mouse can be translated into the far red brightness to regulate the gene expression.

Design of an engineered cell to control the response of the far red light through a smartphone to achieve diabetes semi-automatic treatment

First, the researchers used the idea of synthetic biology to design custom cells that synthesize the gene expression of far red light, which can produce any desired report gene or drug protein, such as green fluorescent protein or insulin, under the irradiation of far red.

When the researchers took the far red light to control the insulin expression of the customized cells, transplanted into the skin of diabetic rats, give diabetic rats direct far red irradiation, can initiate subcutaneous transplanted cells to produce insulin, and play a good hypoglycemic effect. With this treatment, the diabetic rats only need 2-4 hours of light per day to keep their blood sugar at normal levels for up to half a month.

 

The researchers used multidisciplinary joint design methods to further design and develop an integrated intelligent control system for diabetes diagnosis and treatment. Using a blood sugar meter to measure the blood sugar of a mouse, it can be transmitted via Bluetooth wireless to a special smart controller (Smart Controller) and smartphone. When the blood sugar value is higher than the pre-set safe blood sugar threshold, the intelligent controller can light the transplanted water gel led complex (Hydroge LED) which contains the customized cells in the mouse, which triggers the production of insulin or GLP-1 by customized cells to reduce blood sugar and maintain blood sugar homeostasis. In addition, when the mobile phone display abnormal, can also be forced to control the intelligent controller, optimize the program treatment.

 

Mark Gomelsky, a molecular biologist at Wyoming University, wrote a commentary on the research. He says the same effect can be achieved by wearing an LED bracelet rather than by implanting the disc into the skin of the human body. However, the modified cells still need to be injected into the body alone, and it is still not clear how long it will take to inject it once.

 

Prof Gomelsky believes that ECNU's technology may not be the best cure for type 1th diabetes, after all, the U.S. Food and Drug Administration just approved the first fully automatic insulin syringe to go public last year. But he believes the technique can be used to control cells that produce genetically modified drugs at the distal end of the treatment of other diseases.